Floatz logo

Amino Acids, Branched-Chain

Cirrhosis Of Liver

Explore 134 assets in Cirrhosis Of Liver
Floatz Rating
BB69/100
Confidence
Indicative
v0.2
Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Modality
mixture
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
Recruiting
Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia
Enrolling By Invitation
Oral Branched-chain Amino Acid Supplementation for Decompensated Cirrhotic Patients
Enrolling By Invitation
Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis
Completed
Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma
Withdrawn
Frailty in Patients With Cirrhosis: Prognostic Value of the Phase Angle in Hospitalized Patients and Effect of Multifactorial Intervention
Completed
Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C
Active Not Recruiting
The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites
Unknown

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Cirrhosis Of Liver

AssetSponsorPhaseRating
Amino Acids, Branched-Chain (this asset)Post Graduate Institute of Medical Education and Research, ChandigarhApprovedBB · 69
VeruprevirAbbVieP3A
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide)General Hospital of Shenyang Military RegionP4BBB
TolvaptanInstitute of Liver and Biliary Sciences, IndiaP4BBB
RibavirinPeking University People's HospitalP4BBB
Cholyl-Lysl-FluoresceinNorgineP3BBB
Normal Human Serum AlbuminKing George's Medical UniversityP4BBB
OmbitasvirAbbVieP3BBB
ColchicinumBeth Israel Deaconess Medical CenterP4BBB

+42 more in the Cirrhosis Of Liver cohort

Other indications for Amino Acids, Branched-Chain

IndicationSponsorPhaseRating
Hepatic EncephalopathyP4B · 62
Traumatic Brain InjuryP2B · 57
Hepatocellular CarcinomaP2CCC · 53

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Amino Acids, Branched-Chain in Cirrhosis Of Liver. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/amino-acids-branched-chain-cirrhosis-of-liver

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →